ArticleJournal of autoimmunity2011
Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditis.
Article in Journal of autoimmunity, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results.Cancer chemotherapy and pharmacology · 2025Article
- Regulatory T Cells in Pathological Cardiac Hypertrophy: Mechanisms and Therapeutic Potential.Cardiovascular drugs and therapy · 2024Review
- Role of mitochondrial metabolic disorder and immune infiltration in diabetic cardiomyopathy: new insights from bioinformatics analysis.Journal of translational medicine · 2023Article
- Targeting regulatory T cells for cardiovascular diseases.Frontiers in immunology · 2023Review
- T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword.Nature reviews. Cardiology · 2019Review
- Myocarditis in Humans and in Experimental Animal Models.Frontiers in cardiovascular medicine · 2019Review
- T-cell immunity in myocardial inflammation: pathogenic role and therapeutic manipulation.British journal of pharmacology · 2017Review
- Berberine Restricts Coxsackievirus B Type 3 Replication via Inhibition of c-Jun N-Terminal Kinase (JNK) and p38 MAPK Activation In Vitro.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- The CXCL10/CXCR3 Axis and Cardiac Inflammation: Implications for Immunotherapy to Treat Infectious and Noninfectious Diseases of the Heart.Journal of immunology research · 2016Review
- Intricacies of cardiac damage in coxsackievirus B3 infection: implications for therapy.International journal of cardiology · 2014Review
- The whole genome sequence of coxsackievirus B3 MKP strain leading to myocarditis and its molecular phylogenetic analysis.Virology journal · 2014Article
- OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Learning from myocarditis: mimicry, chaos and black holes.F1000prime reports · 2014Review
- Viral myocarditis: from experimental models to molecular diagnosis in patients.Heart failure reviews · 2013Review
- The heart of the matter: protection of the myocardium from T cells.Journal of autoimmunity · 2013Review
- The autoimmune side of heart and lung diseases.Clinical reviews in allergy & immunology · 2013Review
- OX40 facilitates control of a persistent virus infection.PLoS pathogens · 2012Article
- Autoimmunity in 2011.Clinical reviews in allergy & immunology · 2012Review
- Update on coxsackievirus B3 myocarditis.Current opinion in rheumatology · 2012Review
- TNF superfamily in inflammatory disease: translating basic insights.Trends in immunology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Myocarditis poses a severe health problem, can lead to dilated cardiomyopathy (DCM) and death, and is thought to be triggered by infections. Enteroviruses such as Coxsackie virus B3 (CVB3) have been implicated as a culprit, since they can cause acute and chronic heart disease in susceptible mice. CVB was detected in human cardiac myocytes in some cases, whereas acute CVB infection was thought to have caused death. Here we studied, whether nasal administration of cardiac myosin (CM) major histocompatibility class (MHC) II peptides CM₉₄₇-₉₆₀ and CM₇₃₅-₇₄₇ and OX40 blockade would be able to ameliorate immunopathology and heart disease in BALB/C mice infected with CVB3. We found that nasal CM-peptide prophylactic treatment significantly reduced myocarditis and mortality by enhancing Treg and IL-10 induction and that blockade of OX40 signaling could reduce heart inflammation when administered late during pathogenesis. Altogether, these results chart the way for novel prevention and intervention strategies for viral myocarditis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.